Skip to main content

Anti-myeloma drug gets clinical trial nod from USFDA

 The US health regulator has cleared Glenmark Pharma's investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody for treatment of multiple myeloma, the company said today.

This is Glenmark's second investigational new drug from its immuno-oncology portfolio to enter clinical trials.

"GBR 1342 is designed to activate the patient's immune system by redirecting immune cells towards tumour tissue, which may lead to targeted destruction of tumours. It is based on Glenmark's proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform," Glenmak said in a BSE filing.

The first-in-human phase 1 study of GBR 1342 will enrol subjects with multiple myeloma who have exhausted available therapies.

"… our flagship biotechnology platform and antibody science are beginning to become a reality for patients now that we have a second oncology candidate entering clinical trials," Glenmark Pharma President and Chief Scientific Officer Kurt Stoeckli said. "While there is still significant development ahead, these steps signify that Glenmark's investment in discovery and development of biologics is rapidly progressing."

The study is being conducted in two parts.

GBR 1342 is also being considered for the treatment of other malignancies, the company said.

Comments

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris...

Combination Vaccine for Kids withdrawn

A vaccine that combines conventional MMR (Measles, Mumps, Rubella) with Chikenpox has been withdrawn in the United States due to a higher rate of seizures in children. In a study children aged 12 to 23 months who received the combined MMR cum Chickenpox vaccine had double the rate of seizures compared to children who got separate vaccine for MMR and chickenpox. This equates to one additional case of convulsion per 2000 vaccinations.

The Influence of TheTourniquet on blood draw

[1] Various methods are used to obtain specimens for hematocrit determination in neonates. We evaluated arterial sampling and found this method to be acceptable. Arterial values correlated closely with simultaneously obtained venous samples. Venous blood obtained with a tourniquet had a significantly higher hematocrit than that obtained without a tourniquet. [2] Influence of tourniquet application on venous blood sampling for serum chemistry, hematological parameters, leukocyte activation and erythrocyte mechanical properties Background: Venous blood sampling is usually performed using a tourniquet to help locate and define peripheral veins to achieve successful and safe venipuncture. Despite widespread usage of tourniquets for venipuncture by medical and laboratory staff, very few are aware of the effects of tourniquet application on laboratory parameters. In addition, definitive guidelines regarding when and how to use a tourniquet for blood sampling are lacking. The aim ...